Arcellx, Inc. Arcellx, Inc.

Arcellx, Inc.

ACLX

Classificação em ações #2786
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Preço da ação
$115.07
Última sincronização: 2026-05-15
Valor de mercado
$6.73B
Variação (1 dia)
0.00%
Variação (1 ano)
32.61%
País
US
Negociar Arcellx, Inc. (ACLX)

Categoria

Healthcare
Histórico de desdobramentos de ações de Arcellx, Inc. (ACLX)
As ações Arcellx, Inc. (símbolo: ACLX) passaram por um total de 0 desdobramentos.
O desdobramento mais recente ocorreu em Oct 20, 2026.
Uma ação ACLX comprada antes de Oct 20, 2026 equivaleria hoje a 0 ações ACLX.
Lista de desdobramentos de ações
Ano Desdobramento Multiplicador Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.
Desdobramentos de ações de empresas semelhantes ou concorrentes
Empresa Número de desdobramentos de ações Multiplicador cumulativo País
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL